United Therapeutics Corporation


Prices are adjusted according to historical splits.

United Therapeutics Corporation Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$10.57 billion
Book Value:
Revenue TTM:
$2.11 billion
Operating Margin TTM:
Gross Profit TTM:
$1.78 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

United Therapeutics Corporation had its IPO on 1999-06-17 under the ticker symbol UTHR.

The company operates in the Healthcare sector and Biotechnology industry. United Therapeutics Corporation has a staff strength of 985 employees.

Stock update

Shares of United Therapeutics Corporation opened at $226.95 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $222.64 - $226.95, and closed at $223.78.

This is a -0.68% slip from the previous day's closing price.

A total volume of 149,100 shares were traded at the close of the day’s session.

In the last one week, shares of United Therapeutics Corporation have slipped by -1.87%.

United Therapeutics Corporation's Key Ratios

United Therapeutics Corporation has a market cap of $10.57 billion, indicating a price to book ratio of 2.8015 and a price to sales ratio of 6.7594.

In the last 12-months United Therapeutics Corporation’s revenue was $2.11 billion with a gross profit of $1.78 billion and an EBITDA of $1.15 billion. The EBITDA ratio measures United Therapeutics Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, United Therapeutics Corporation’s operating margin was 51.97% while its return on assets stood at 11.22% with a return of equity of 17.92%.

In Q2, United Therapeutics Corporation’s quarterly earnings growth was a positive 117.4% while revenue growth was a positive 27.8%.

United Therapeutics Corporation’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $17.85 per share while it has a forward price to earnings multiple of 14.5349 and a PEG multiple of 1.0244. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into United Therapeutics Corporation’s profitability.

United Therapeutics Corporation stock is trading at a EV to sales ratio of 5.8955 and a EV to EBITDA ratio of 11.101. Its price to sales ratio in the trailing 12-months stood at 6.7594.

United Therapeutics Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$6.68 billion
Total Liabilities
$370.30 million
Operating Cash Flow
Capital Expenditure
$44.70 million
Dividend Payout Ratio

United Therapeutics Corporation ended 2024 with $6.68 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.68 billion while shareholder equity stood at $5.41 billion.

United Therapeutics Corporation ended 2024 with $0 in deferred long-term liabilities, $370.30 million in other current liabilities, 700000.00 in common stock, $5.54 billion in retained earnings and $0 in goodwill. Its cash balance stood at $1.07 billion and cash and short-term investments were $4.70 billion. The company’s total short-term debt was $0 while long-term debt stood at $800.00 million.

United Therapeutics Corporation’s total current assets stands at $3.21 billion while long-term investments were $2.02 billion and short-term investments were $3.64 billion. Its net receivables were $272.70 million compared to accounts payable of $292.00 million and inventory worth $103.30 million.

In 2024, United Therapeutics Corporation's operating cash flow was $-227200000.00 while its capital expenditure stood at $44.70 million.

Comparatively, United Therapeutics Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

United Therapeutics Corporation stock is currently trading at $223.78 per share. It touched a 52-week high of $283.09 and a 52-week low of $283.09. Analysts tracking the stock have a 12-month average target price of $282.

Its 50-day moving average was $232.04 and 200-day moving average was $238.91 The short ratio stood at 4.98 indicating a short percent outstanding of 0%.

Around 177% of the company’s stock are held by insiders while 9997.3% are held by institutions.

Frequently Asked Questions About United Therapeutics Corporation

The stock symbol (also called stock or share ticker) of United Therapeutics Corporation is UTHR

The IPO of United Therapeutics Corporation took place on 1999-06-17

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.


1040 Spring Street, Silver Spring, MD, United States, 20910